Joshua A. Kazam
Known title: DirectorCIK: 0001221355
Joshua A. Kazam's purchase track record
Joshua A. Kazam has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/12/2022 | ALLO | $189K | -28.9% | -0.7% | -19.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALLO | ▲ Buy | Option Exercise | 47,700 | $0 | 6/18/2026 | View on chart |
| ALLO | ▲ Buy | Option Exercise | 47,700 | $0 | 12/18/2025 | View on chart |
| ALLO | ▲ Buy | Grant | 44,178 | $0 | 6/15/2022 | View on chart |
| ALLO | ▼ Sell | Gift | 412,618 | $0 | 3/7/2022 | View on chart |
| ALLO | ▼ Sell | Other | 412,618 | $0 | 3/7/2022 | View on chart |
| ALLO | ▲ Buy | Open Market | 15,000 | $189K | 1/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Allogene CFO Departure Comes Amid CAR-T Sector Safety Concerns
Allogene announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, marking a leadership transition at a challenging time for the company. The timing coincides with broader scrutiny of CAR-T therapies for autoimmune conditions after competing trials from Novartis and Bristol Myers were paused over safety concerns. On the clinical front, the company indicated that if its minimal residual disease data holds, it could represent a significant shift in its business outlook. The stock has traded within a $1.04 to $4.46 range over the past year.
Allogene CFO Departure Comes Amid CAR-T Sector Safety Concerns. Allogene announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, marking a leadership transition at a challenging time for the company. The timing coincides with broader scrutiny of CAR-T therapies for autoimmune conditions after competing trials from Novartis and Bristol Myers were paused over safety concerns. On the clinical front, the company indicated that if its minimal residual disease data holds, it could represent a significant shift in its business outlook. The stock has traded within a $1.04 to $4.46 range over the past year.